ReviewOpen medicine (Warsaw, Poland)2021
The ambiguous role of mannose-binding lectin (MBL) in human immunity.
Review in Open medicine (Warsaw, Poland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- From Airway Inflammation to Molecular Remodeling: Integrating YKL-40, MBL and Epigenetic Biomarkers in Asthma and COPD.Biomolecules · 2026Review
- Individuals with ABO Groups Show Significant Differences in Levels of Circulating Biomarkers Related to Inflammation, Apoptosis, Endothelial Dysfunction, Tissue Remodeling and Neurodegeneration: A Pilot Study.Diseases (Basel, Switzerland) · 2026Article
- Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies.Diagnostics (Basel, Switzerland) · 2026Review
- Glycoproteomic and genetic analysis of N-glycosylation of complement component C3 reveals immune pathway regulation.Genome biology · 2026Article
- Mannose-binding lectin 2 secreted by hepatocellular carcinoma cells recruits and activates natural killer cells to reshape an immune-activated microenvironment.PLoS biology · 2026Article
- Research progress on the lectin pathway of complement in IgA nephropathy.Frontiers in immunology · 2026Review
- Gene sequencing andJournal of advanced veterinary and animal research · 2025Article
- Association between MBL2 gene polymorphism and protection against leprosy in a population of northeastern brazil: a case-control study.Scientific reports · 2025Article
- Article
- Differential Expression of ARG1 and MRC2 in Retinal Müller Glial Cells During Autoimmune Uveitis.Biomolecules · 2025Article
- Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases.Journal of inflammation research · 2025Article
- Innate Immune Response to Viral Infection.Advances in experimental medicine and biology · 2025Review
- Genomic Insights into Host Susceptibility to Periprosthetic Joint Infections: A Comprehensive Literature Review.Microorganisms · 2024Review
- Analysis of Mannose-Binding Lectin Protein and mRNA Levels on Selected Chicken Breeds in South Africa.Veterinary medicine and science · 2024Article
- Accelerated wound healing and reduced scar formation induced by D-mannose: a possible role of mannose binding lectin.Archives of dermatological research · 2024Article
- A Nanoplasmonic Assay for Point-of-Care Detection of Mannose-Binding Lectin in Human Serum.ACS applied materials & interfaces · 2024Article
- Reproductive Effect by Rheumatoid Arthritis and Related Autoantibodies.Rheumatology and therapy · 2024Review
- Unravelling mechanisms of bacterial recognition by Acanthamoeba: insights into microbial ecology and immune responses.Frontiers in microbiology · 2024Review
- Targeting motility and chemotaxis as a strategy to combat bacterial pathogens.Microbial biotechnology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mannose-binding lectin (MBL) and lectin complement pathway have become targets of increasing clinical interest. Many aspects of MBL have been recently explored, including the structural properties that allow it to distinguish self from non-self/altered-self structures. Experimental evidences have declared the additional 5'- and 3'-variants that in amalgamation with well-known secretor polymorphisms change MBL function and concentration. Moreover, the current review highlights the differential behavior of MBL on exposure with extra/intracellular pathogens and in autoimmune diseases, stressing the fact that "high MBL levels can increase diseases susceptibility," a paradox that needs justification. Attributable to these discrepancies, no absolute level of MBL deficiency could be defined so far and thus must be interpreted for specific diseases through case-control population-specific designs. Overall, it is evident that further research is needed about MBL and the lectin pathway of complement. Particularly, the transformative role of MBL over evolution is of interest and its role with regard to pathogenesis of different diseases and potential therapeutic targets within the respective pathways should be further explored. Apart from this, it is necessary to adopt an extensive locus-wide methodology to apprehend the clinical significance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.